PATENT CLAIM ANALYSIS

Application Number: 16216714
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["435", "006140"]

Abstract:
Process for the identification of compounds for treating cancer. The invention relates to a method for identifying candidate compounds for use as therapeutic agents for the treatment of cancer, among those who are able to activate the MDA-5 protein or increase NOXA protein levels and to trigger autophagy. It is based on the fact that activation of dsRNA sensor MDA-5 is able to trigger the destruction of cancer cells by activation both autophagy and apoptosis, autonomously and selectively in tumor cells, without provoking the stabilization of the natural antagonist NOXA, MCL-1. The invention also relates to the use of double-stranded RNAs of the same or similar nature such as polyinosinic-polycytidylic acid (pIC), complexed with carriers such as polyethylenimine polycation (PEI), for the manufacture of medicines for the treatment of cancer.

Claim (Index 46):
A method to identify a therapeutic agent for the treatment of cancer comprising:\n a) contacting a candidate compound with a cancer cell, or cell from a cell line derived from cancer cells; b) determining the level of activation of a family helicase MDA-5 or the level of Phorbol-12-myristate-13-acetate-induced protein 1(NOXA) expression in the cell of step a); c) determining induction of autophagy in the cell from step a); d) comparing the data obtained in steps b) and c) with those observed in controls comprising the same cells in the absence of the candidate compound; e) selecting as therapeutic agent for the treatment of cancer a compound which has given rise to an increase in the parameter or parameters determined in steps b) and c) in comparison with the controls, wherein the candidate compound is a complex comprising a viral double-stranded RNA (dsRNA) synthetic analogue and a polycation, wherein\n (i) the dsRNA synthetic analogue consists of a pIC (polyinosine-polycytidylic acid), and \n (ii) the polycation consists of a linear polyethyleneimine (PEI); \n and wherein \n (iii) the pIC and linear PEI are complexed at a ratio of nitrogen residues of linear PEI per dsRNA phosphate of 1 to 5; and \n (iv) the length of the pIC is at least 25 nucleotides per strand.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 98.0
- Lexical Diversity: 1.7561
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15753328', '14352983', '13784903', '12836626', '15176812']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5644721751683086
- 35 USC 102 Novelty (BERT): 0.5114292026330665
- Combined Prediction Score: 0.5591678779147845
- Mean Citation Score: 271.1865839999999
- Max Citation Score: 287.2212
- Similarity Product: 216.605480697012

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test